Item 7.01 Regulation FD Disclosure.
In connection with its participation in the J.P. Morgan Healthcare Conference,
NanoString Technologies, Inc. announced on January 8, 2023 certain preliminary
results at and for the quarter and year ended December 31, 2022. A copy of the
press release is furnished herewith as Exhibit 99.1 and is incorporated herein
by reference.
The Company announces material information to the public through a variety of
means, including filings with the Securities and Exchange Commission, press
releases, public conference calls, the Company's website (www.nanostring.com),
its investor relations website (investors.nanostring.com), and its news site
(investors.nanostring.com/press-releases). The Company uses these channels, as
well as social media, including its Twitter account (@nanostringtech), LinkedIn
account (www.linkedin.com/company/nanostring-technologies), and Facebook page
(www.facebook.com/NanoStringTechnologies), to communicate with investors and the
public about the Company, its products, and other matters. Therefore, the
Company encourages investors, the media, and others interested in the Company to
review the information it makes public in these locations, as such information
could be deemed to be material information.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release dated January 8 , 202 3 .
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
The information furnished in this Current Report on Form 8-K and Exhibit 99.1
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
© Edgar Online, source Glimpses